Objectives: To provide a mathematical background for understanding the phenomenon of analyte hemodilution using a kinetic analysis. 
Results: The analyses demonstrate how serum PSA can be affected by plasma volume as well as body mass and how hemodilution due to obesity can be at least partly corrected for by expressing PSA in units of total mass or total mass density.
Conclusions: At a time when obesity is prevalent, expressing analytes in units of total mass may make them relate more closely to disease status and prognosis.
When an organ releases an analyte into the blood, the principle of conservation of mass implies that the rate of change in concentration of the analyte must reflect the mass of analyte entering the blood as well as the loss of analyte from the bloodstream. If y symbolizes the concentration of analyte, then the foregoing implies the following kinetic equation:
Here, M symbolizes the mass of the organ (g), V symbolizes plasma volume (mL), and α reflects the amount of analyte released per unit time and per unit weight of the organ (ng/(day × g)). β provides the rate for loss of the analyte from the blood (1/days), regardless of whether that loss is physiologic or chemical. Organs may release analytes when they are damaged, as with cardiac markers during acute myocardial infarction, or when they harbor a tumor, as with serum prostate-specific antigen (PSA) and prostate cancer. In the first example, α reflects the size of the infarct. 1 In the second, α reflects the size and grade of the tumor as well as any benign tissue capable of releasing PSA. 3 Although V is not routinely measured in patients, V is reflected by body size. 4, 5 Thus, at a time when obesity has become common, 6 the levels of any analyte may 
Materials and Methods

Model for Plasma Volume
Data providing plasma volume (V) determined by the Evans blue dye dilution method were obtained from two prior studies 4, 5 to yield a total of 172 subjects, and regression analysis was performed to relate V to height, weight, sex, and hematocrit (Hct). The mean value of V in the men of these data was 3,063 mL, and other details of the study population are given in ❚Table 1❚.
Kinetic Model
For this analysis, y symbolizes the concentration of PSA in the plasma, dy/dt symbolizes PSA velocity, and M symbolizes prostate weight. Although equation (1) is a first-order differential equation with a solution (see supplemental material, which can be found at American Journal of Clinical Pathology online), the solution is too complex for practical use. Nevertheless, a simplified form of equation (1) can be obtained. For example, many have observed that serial values of PSA follow an exponential pattern 7, 8 (see Humphrey and Vollmer 7 for an early review), and this exponential pattern implies that at any time prior to diagnosis and treatment, the PSA velocity is proportional to the PSA concentration. Mathematically, this statement becomes
Here, ρ has been termed a relative velocity, 9 because it gives the PSA velocity relative to the value of PSA at the same time and can be written as
ρ has been shown to be prognostic and to relate to tumor stage and growth rate as well as to outcomes. 7, 9 Furthermore, if PSA measurements at two different times, t1 and t2, are symbolized as y1 and y2, then ρ can be estimated as r ln y2 y1 t2 t1
with ln symbolizing the natural logarithm. 9 Equation (4) implies that ρ equals .693/(PSA doubling time). Finally, substituting equation (2) into equation (1) and solving for y yields
This result allows us to demonstrate the expected relationships between serum PSA and V, body weight, and M. 
Results
Relationship of Plasma
Serum PSA and Hemodilution
Although examination of equation (5) indicates that the concentration of PSA (ie, y) should be inversely related to V, the magnitude of this hemodilution is not apparent (5) to demonstrate how PSA relates to V. For example, let us assume that the weight of the prostate is 53 g, because this is what a study of over 13,000 men found. 3 Next, let β assume its mean value of .26 (1/day) found by following PSA levels after prostatectomy, 7 and let ρ have the value of .00077, which was the mean found at the time of diagnosis of prostate cancer for 100 men. 8 Let V assume its mean value of 3,063 mL. 4, 5 For a range of PSA values from 1 to 15 ng/mL, the corresponding median value for α would be 121 (1/(ng × day)). Using these values and allowing V to vary, ❚Figure 2❚ demonstrates how serum PSA (y-axis) can be affected by hemodilution. Furthermore, by fixing height at 168 cm (mean of the data for men in Figure 1 ), ❚Figure 3❚ demonstrates how serum PSA can be affected by body weight (x-axis). Although these results flow naturally from the kinetic model, similar results have also been obtained empirically from patient data.
3,10
PSA Mass and PSA Mass Density
Multiplying both sides of equation (5) by V yields an equation for PSA mass (PSAM) as follows:
Thus, unlike serum PSA, PSAM at least over small time periods reflects just α, W, ρ, and β. In this way, the kinetic model predicts that PSAM should at least partly correct ❚Figure 1❚ Plot of the predicted plasma volume (Vp) obtained from the linear regression model of Table 1 vs the plasma volume observed in the 172 patients used for the analysis.
❚Figure 2❚ Plot of the expected relationship between serum prostate-specific antigen and plasma volume as obtained from the kinetic model leading to equation (5) .
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AJCP / Original article for the effects of hemodilution. Empirical data have verified this result. 3, [11] [12] [13] [14] Next, dividing both sides of equation (5) by M yields an equation for PSA mass density (PSAMD) as follows:
Equation (7) demonstrates that PSAMD reflects just the quotient α / (ρ + β), so that it brings us one step closer to knowing the value of α, the variable most closely related to the amount and grade of tumor. Note, however, that both numerator and denominator contain variables (α and ρ) that reflect the mass of tumor. If prostate mass is estimated by ultrasound and if plasma volume can be estimated from height, weight, and Hct, then PSAMD can be calculated as PSA * V / M. Thus, PSAMD may become a better prognosticator than PSA. In fact, some have found that PSAMD is more closely related to tumor volume than PSAM. 12 Nevertheless, PSAMD remains inversely related to the sum (ρ + β). Thus, higher levels of PSAMD could be due to a higher level of α or to lower levels of ρ and β. Furthermore, because one study demonstrated that removal of PSA takes place in the liver, 15 it is possible that varying levels of β could be due to variations in liver function.
Discussion
The above analysis provides a physiologic background for understanding how the amount of any analyte can be affected by body weight, and the results suggest that obesity-related hemodilution may be at least partly corrected for by multiplying the concentration by an estimate of plasma volume to yield the amount of analyte in units of mass. Undoubtedly, the product introduces noise due to the level of error documented in Figure 1 , and it is likely that additional noise comes from unaccounted levels of α1 antichymotrypsin. Nevertheless, some have found that PSAM and PSAMD provide useful prognostic information. [11] [12] [13] [14] Other laboratory analytes that may be candidates for converting to mass units include hemoglobin, creatinine, glucose, troponins, and even blood cell counts. For example, absolute counts of monocytes can be multiplied by an estimate of blood volume to yield an overall monocyte mass. The early successes for PSAM and PSAMD suggest that more emphasis be given to the importance of plasma volume in the obese population. For example, it is possible that additional studies relating plasma volume to height and weight could improve on the results from Table 2 . Finally, the results suggest that laboratorians undertake additional empirical studies to compare how patient outcomes relate to the amount of analyte in units of mass vs units of concentration.
